Thus, the beneficial effects of exogenous TFEB expression on the clearance of Aβ and tau in in vitro and in vivo models of AD are clear, while the contribution of endogenous TFEB to AD progression is less well defined. This evidence concerns the gene MAPT and Alzheimer disease.